Prospective Observational Study Monitoring Circulating Tumor DNA in Resectable Colorectal Cancer Patients Undergoing Radical Surgery: **GALAXY Study in CIRCULATE-Japan (trial in progress)**




1. Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 2. Department of Surgery and Science, Graduate School of Medical Science, Kyushu University, 3. Department of Surgery, National Hospital Organization Osaka National Hospital, 4. Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, 5. Department of Biostatistics, Yokohama City University School of Medicine, 6. Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 7. Department of Internal Medicine, Kushiro Rosai Hospital, 8. Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, 9. Natera, Inc., San Carlos, CA, USA

Background

- **D**Adjuvant chemotherapy has reduced the risk of tumor recurrence and improved survival in patients with resected colorectal cancer (CRC).
- **D**Early clinical utility of circulating tumor DNA (ctDNA) pre- and post-surgery has been reported across various types of solid tumors, including CRC^{1,2,3}.
- **D**Analysis of ctDNA status can be utilized as a non-invasive biomarker for risk stratification and to monitor the effectiveness of adjuvant chemotherapy.
- **D**We are conducting a prospective, observational study to monitor the ctDNA status and to establish the registry data in stage II-IV CRC patients who underwent surgical resection as part of CIRCULATE-Japan project (Fig. 1).

CIRCULATE-Japan project overview

Figure 1. CIRCULATE-Japan study schema



The VEGA trial:

A randomized trial to evaluate the non-inferiority of observation vs. adjuvant CAPOX in GALAXY participants who are high-risk stage II or low-risk stage III with absence of ctDNA at 1-month post-surgery.

The ALTAIR trial:

A randomized trial to evaluate the superiority of FTD/TPI over placebo in GALAXY participants with ctDNA that remains positive after the standard adjuvant therapy.

Hiroki Yukami¹, Saori Mishima¹, Daisuke Kotani¹, Eiji Oki² Hiroya Taniguchi¹, Yoshiaki Nakamura¹, Takeshi Kato³, Ichiro Takemasa⁴, Takeharu Yamanaka⁵, Hiromichi Shirasu⁶, Kentaro Sawada⁷, Hiromichi Ebi⁸, Alexey Aleshin⁹, Paul R. Billings⁹, Masaki Mori², Takayuki Yoshino¹

Study design Figure 2. GALAXY study schema resection Pre-op 2500 patients Tumor markers ♦ CT


Primary endpoint: ■ Disease-free survival Secondary endpoint:

- Overall survival
- ctDNA status at each time point
- Association between clinical characteristic and gene alterations
- Comparison of time to relapse by ctDNA and computed tomography (CT)
- □ The study utilizes a personalized, tumor-informed ctDNA assay (Signatera[™] bespoke multiplex-PCR NGS assay) based on whole-exome sequencing of tumor tissue sample.
- □ The procedure of ctDNA assay is outlined in "Schematic of Molecular Protocol (Fig. 3)".
- □ Blood samples will be collected at following time points; at pre-surgery and 1, 3, 6, 9, 12, 18, and 24 months of post-surgery, and at the same time the CT image will be performed.
- □ Mutations in RAS, BRAF and microsatellite instability tests by validated PCR methods will be assessed centrally.

Key eligibility criteria:

- Histologically confirmed colorectal adenocarcinoma
- The primary location of the tumor is the colon or rectum (excluding appendix, and anal canal cancer). ■Curative resection is planned for stage II or III in UICC 8th edition, or R0 resection is planned for relapse or stage IV colorectal cancer.
- ■Age ≥ 20 years
- ■ECOG PS 0-1
- Written informed consent

Figure 3. Schematic of Molecular Protocol



- WES analysis of tumor tissue and blood samples will be performed for each patient to select the patientspecific and clonal 16 single nucleotide variants (SNV).
- Patient-specific multiplex-PCR assays targeting 16 somatic SNV and NGS will be used to detect patient-specific tumor DNA in blood collected pre- and postsurgery.



